Cost-effectiveness of 3 statin sample policies in post-myocardial infarction patients

American Journal of Pharmacy Benefits

Volumn 5, Issue 2, 2013, Pages

  Kaakeh, Rola ^a   Hutton, David W ^b   Funk, Kylee ^c   Gatwood, Justin ^c   Chan, Bernadette ^c   Salah Ud Din, Maha ^c  

^a Sullivan University College of Pharmacy   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; MORTALITY; PATIENT COMPLIANCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; SENSITIVITY ANALYSIS;

EID: 84876564436     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med. 2007;356(17): 1742-1750.
2. Gellad WF, Huskamp HA, Li A, Zhang Y, Safran DG, Donohue JM. Use of prescription drug samples and patient assistance programs, and the role of doctorpatient communication. J Gen Intern Med. 2011;26(12):1458-1464.
3. Adair RF, Holmgren, L. Do drug samples influence resident prescribing behavior? a randomized trial. Am J Med. 2005;118(8):881-884.
4. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med. 2000;15(7):478-483.
5. IMS Health. U.S. physicians responsive to patient requests for brand-name drugs. http://www.imshealth.com/ims/portal/front/articleC/0,2777, 6599_3665_ 1003811, 0.html. Published 2010. Accessed September 27, 2011.
6. Favole J. Drug makers provide view of sampling practices [Business]. The Wall Street Journal. June 5, 2010.
7. Conklin M, Culley E, O'Donnell J. Case study of the effects of office-based generic drug sampling on antibiotic drug costs and first-line antibiotic prescribing ratios. J Manag Care Pharm. 2009;15(1):55-61.
8. Scott AB, Culley E, O'Donnell J. Effects of physician office generic drug sampling system on generic dispensing ratios and drug costs in a large managed care organization. J Manag Care Pharm. 2007;13(5):412-419.
9. Jones S. No free pills for Carilion patients: policy banning free samples targets ties between physicians and drugmakers. The Roanoke Times. May 2, 2010.
10. Rabin R. Free drug samples? bad idea, some say [Health]. The New York Times. May 1, 2007.
11. Rubin R. Doctors ditch drug samples to avoid influencing treatment [Health & Behavior]. USA Today. December 1, 2008.
12. IMS Institute for Healthcare Informatics. The Use Of Medicines in the United States: Review of 2010. http://www.imshealth.com/deployedfiles/imshealth/Global/ Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf. Published April 2011. Accessed April 23, 2011.
13. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol. 2004;44(3): E1-E211.
14. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006;12(9): 509-17.
15. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006;12(Spec No.):SP11-SP19.
16. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15): 1253-1258.
17. Miesner AR, Allen DP, Koenigsfeld CF, Wall GC. Effect of sample medication restrictions on prescribing at a private clinic. Arch Intern Med. 2009;169(13): 1241-1242.
18. Rodin HA, Heaton AH, Wilson AR, Garrett NA, Plocher DW. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit. Am J Manag Care. 2009;15(12):881-888.
19. Shrank WH, Stedman M, Ettner SL, et al. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use. J Gen Intern Med. 2007;22(9):1298-1304.
20. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract. 2008;62 (3): 480-484.
21. Ellis JJ, Erickson SE, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638-645.
22. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avon J. Longterm persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4): 455-461.
23. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-186.
24. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419-1424.
25. Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008;117(10):1261-1268.
26. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary artery disease [published correction appears in J Card Fail. 1998;4(4):367]. J Card Fail. 1997;3(4):249-254.
27. Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010;4(6):462-471.
28. Red Book. Montvale, NJ: Thomson Reuters (Healthcare) Inc; 2010:349, 536, 674, 727.
29. Healthcare Cost and Utilization Project (HCUP). Overview of the Nationwide Inpatient Sample (NIS). HCUP databases. 2007-2009. http://www.hcup-us.ahrq gov/nisoverview.jsp. Published June 2012. Accessed June 18, 2012.
30. Genworth Financial. National Data from the Genworth 2012 Cost of Care Survey. http://www.genworth.com/content/etc/medialib/genworth_v2/pdf/ltc_ cost_of_care.Par.20922.File.dat/USA_gnw.pdf. Published 2012. Accessed June 18, 2012.
31. MetLife Mature Market Institute. Market Survey of Long-Term Care Costs. http://www.metlife.com/assets/cao/mmi/publications/studies/2011/mmi-marketsurvey- nursing-home-assisted-living-adult-day-services-costs.pdf. Published October 2011. Accessed June 18, 2012.
32. Centers for Medicare & Medicaid Services. Last year of life expenditures. MCBS Profiles. Issue No. 10. https://www.cms.gov/Research-Statistics-Data-and Systems/Research/MCBS/downloads/issue10.pdf. Published May 2003. Accessed June 18, 2012.
33. Ahmed A, Allman RM, DeLong JF. Predictors of nursing home admission for older adults hospitalized with heart failure. Arch Gerontol Geriatr. 2003;36(2): 117-126.
34. Pope GC, Kautter J, Ellis RP, et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev. 2004;25(4):119-141.
35. Retchin SM, Brown RS, Yeh SC, Chu D, Moreno L. Outcomes of stroke patients in Medicare fee for service and managed care. JAMA. 1997;278(2):119-124.
36. Hickenbottom SL, Fendrick AM, Kutcher JS, Kabeto MU, Katz SJ, Langa KM. A national study of the quantity and cost of informal caregiving for the elderly with stroke. Neurology. 2002;58(12):1754-1759.
37. American Medical Association. CPT code/relative value search. CodeManager. https://ocm.ama-assn.org/OCM/CPTRelativeValueSearch.do?submitbutton=accept. Published 2011. Accessed September 27, 2011.
38. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and use of generic drug therapies. Am J Manag Care. 2009;15(7):450-456.
39. Centers for Medicare & Medicaid Services. Medicare program; inpatient hospital deductible and hospital and extended care services coinsurance amounts for CY 2012. Fed Regist. 2011;76:67568-67570.
40. Ara R, Pandor A, Stevens J, Rees A, Rafia R. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technol Assess. 2009;13(34):1-118.
41. Rosen VM, Taylor DC, Parekh H, et al. Cost effectiveness of intensive lipidlowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics. 2010;28(1):47-60.
42. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78(6):393-403.
43. Backes JM, Moriarty PM, Ruisinger JF, Gibson CA. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol. 2007; 100(3):554-555.
44. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statininduced rhabdomyolysis. Am J Med. 2006;119(5):400-409.
45. Glueck CJ, Aregawi D, Agloria M, et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther. 2006;28(6):933-942.
46. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy- 3-methlyglutaryl co-enzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med. 2000;132(10):780-787.
47. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analyses of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109-124.
48. Arias E. United States life tables, 2000. Natl Vital Stat Rep. 2002;51(3):1-38.
49. Bureau of Labor Statistics. National occupational employment and wage estimates United States. http://www.bls.gov/oes/current/oes_nat.htm#39-0000. Published May 2011. Accessed June 18, 2012.
50. Bureau of Economic Analysis. Gross Domestic Product: First Quarter 2012 (Advance Estimate) [news release]. http://www.bea.gov/newsreleases/national/gdp/2012/ pdf/gdp1q12_adv.pdf. Published April 27, 2012. Accessed June 18, 2012.
51. Fu AZ, Kattan MW. Utilities should not be multiplied: evidence from the preference-based scores in the United States. Med Care. 2008;46(9):984-990.
52. Pletcher M, Lazar L, Bibbins-Domingo K, et al. Comparing impact and costeffectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150(4):243-254.
53. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterollowering therapies according to selected patient characteristics. Ann Intern Med. 2000;132(10):769-779.
54. Shrank WH, Choudhry NK, Solomon DH, et al. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009;157(4): 613-619.
55. Lundy K, for the Kaiser Family Foundation. Prescription Drug Trends. Publication 3057-08. http://www.kff.org/rxdrugs/upload/3057-08.pdf. Published May 2010. Accessed September 27, 2011